(Q44798829)

6 December 2017

title

Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis (English)

1 reference

6 December 2017

1 reference

Conor C Murphy

1

0 references

author name string

William H Ayliffe

2

1 reference

6 December 2017

Anthony Booth

3

1 reference

6 December 2017

David Makanjuola

4

1 reference

6 December 2017

Peter A Andrews

5

1 reference

6 December 2017

David Jayne

6

1 reference

6 December 2017

language of work or name

1 reference

1 February 2004

1 reference

6 December 2017

1 reference

6 December 2017

volume

111

1 reference

6 December 2017

issue

2

1 reference

6 December 2017

page(s)

352-356

1 reference

The possible impact of uveitis in blindness: a literature survey

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Episcleritis and scleritis: clinical features and treatment results

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Clinical patterns and associated conditions in chronic uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Uveitis and systemic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Duke-Elder Lecture: new concepts on the role of autoimmunity in the pathogenesis of uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Cytokines: their role in uveal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Safety and efficacy of TNFalpha blockade in relapsing vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Uveitis: pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

The biology of cachectin/TNF--a primary mediator of the host response

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Cytokines in human intraocular inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Effect of infliximab on threatening panuveitis in Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

Review article: safety of infliximab in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900721-8

7 January 2021

10.1016/S0161-6420(03)00721-8

Identifiers

DOI

1 reference

6 December 2017

1 reference